About Arcturus Therapeutics Holdings (ARCT)
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
ARCT Key Statistics
| Current Price | $7.25 | Market Cap | $206 million |
|---|---|---|---|
| Daily Change | -4.35% | Volume | 565K |
| 52-Week High | $24.17 | 52-Week Low | $5.85 |
| Sector | Healthcare | Industry | Biotechnology |
ARCT Price Performance
Arcturus Therapeutics Holdings stock has returned -4.35% over the past day, -12.86% over the past week, +1.12% over the past month, and -4.23% over the past three months. The stock trades between a 52-week low of $5.85 and a high of $24.17.